Prediction of 6-thioguanine nucleotides levels in Japanese patients with inflammatory bowel diseases during long-term thiopurine administration

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 5, 2010, Pages 608-614

  Kochi, Shuji ^a   Matsumoto, Takayuki ^a   Esaki, Motohiro ^a   Jo, Yukihiko ^a   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

6 mercaptopurine; 6 thioguanine nucleotides; Azathioprine; Inflammatory bowel disease; Mean corpuscular volume

Indexed keywords

AZATHIOPRINE; HEMOGLOBIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; THIOGUANOSINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; JAPANESE; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; BIOMARKERS, PHARMACOLOGICAL; CHI-SQUARE DISTRIBUTION; ERYTHROCYTE VOLUME; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; JAPAN; LOGISTIC MODELS; MALE; NUCLEOTIDES; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; THIOGUANINE;

EID: 77951673607     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521003642559     Document Type: Article

References (32)

1. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathi-oprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-489 (Pubitemid 34638866)
2. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-433 (Pubitemid 126733803)
3. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53. (Pubitemid 41820634)
4. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;2:CD000067.
5. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;2:CD000545.
6. Elion GB. The pharmacology of azathioprine. Ann NY Acad Sci 1993;685:400-407
7. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-646 (Pubitemid 32378583)
8. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-713 (Pubitemid 30171620)
9. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006;130:1047-1053
10. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastro-enterological Association Institute technical reviewoncorticos-teroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-987 (Pubitemid 43374543)
11. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003;38:740-746 (Pubitemid 37161337)
12. Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008;23:1373-1377
13. Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thio-guanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000;135:256-262 (Pubitemid 30132348)
14. Jobson B, Garza A, Sninsky A. Red cell mean corpuscular volume (MCV) correlates with 6 thioguanine nucleotide (6TG) levels during azathioprine or 6-MP therapy for Crohn's disease (abstract). Gastroenterology 2001; 120(Suppl 1):A4.
15. Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001;36:71-76 (Pubitemid 32147184)
16. Thomas CW Jr, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003;9:237-245
17. D'Halluin PN, Tribut O, Branger B, Lebreton C, Bretagne JF, Bentue-Ferrer D, et al. RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine. Gastroenterol Clin Biol 2005;29:1264-1269 (Pubitemid 43170258)
18. Best WR, Becktel JM, Singleton JW, KernF Jr. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-444
19. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971-976
20. Sandborn WJ. Rational dosing of azathioprine and 6-mer-captopurine. Gut 2001;48:591-592
21. Sandborn WJ, Hanauer SB. Systemic review: the pharma-cokinetic profiles of oral mesalazine formulations and mesa-lazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29-42.
22. Lennard L, Singleton HJ. High-performance liquid chro-matographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83-90.
23. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163: 670-675
24. Wickramasinghe SN, Dodsworth H, Rault RM, Hulme B. Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation 1974;18:443-446
25. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813-821 (Pubitemid 28452927)
26. McGrath BP, Ibels LS, Raik E, Hargrave MJ. Erythroid toxicity of azathioprine. Macrocytosis and selective marrow hypoplasis. Q J Med 1975;44:57-63.
27. Revel-Vilk S, Tamary H, Broide E, Zoldan M, Dinari G, Zahavi I, et al. Serum transferrin receptor in children and adolescents with inflammatory bowel disease. Eur J Pediatr 2000;159:585-589 (Pubitemid 30469445)
28. Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG. Thio-purine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroen-terol 2006;101:2769-2776 (Pubitemid 44902649)
29. Heckmann JM, Lambson EM, Little F, Owen EP. Thiopur-ine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J Neurol Sci 2005;231:71-80. (Pubitemid 40432029)
30. Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009;24:1258-1264
31. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, et al. Measurement of thiopur-ine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49: 665-670
32. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99:1744-1748 (Pubitemid 39237503)